Solid investor interest as Ambit raises new funds for quizartinib-led pipeline
This article was originally published in Scrip
Ambit Biosciences closed the first $25 million tranche of a $50 million preferred stock financing to support late-stage development of its lead drug candidate quizartinib (AC220), as the private San Diego-based company prepares its Phase II data in the treatment of acute myeloid leukemia (AML) for presentation at the American Society of Hematology (ASH) annual meeting.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.